Erika P. Hamilton, MD, discusses the role of T-DXd in HER2+ and HER2-low breast cancer, the evolution of CDK4/6 inhibitors in HR+ disease, and how genetic testing supports precision medicine research. @ErikaHamilton9 @SarahCannonDocs #bcsm #OncLiveIPC https://t.co/KYnlhERuBx (@OncLive)

A new @ASCO study, co-led by the HICCC's Dr. Dawn Hershman (@DrDawnHershman) has been awarded $11 million in research funding by @PCORI to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer. @ColumbiaMed https://t.co/wQCQAVjBg7 (@columbiacancer)

Incredibly excited for this opportunity with support from @PCORI to study how we can help older patients with metastatic breast cancer better tolerate therapy w/ CDK4/6 inhibitors, & stay on treatment longer. @ASCO @DrDawnHershman @elmayermd @LGM_Biostats https://t.co/oGe5Fs9yQI (@jrgralow)

Today @PCORI awarded $11M to @ASCO to study CDK4/6 inhibitor dosing in older patients w/metastatic breast cancer. Despite BC being more prevalent in people <65, few are included in current CDK4/6 trials. Study will be co-led by @elmayermd @DFCI_BreastOnc https://t.co/YYKIlCDYvf (@DanaFarberNews)

We’re pleased to announce ASCO has been awarded $11M of @PCORI research funding to study CDK4/6 inhibitors dosing in older adults w metastatic breast cancer. Led by our CMO @jrgralow, the aim is to improve outcomes & fill a real-world evidence gap. More: https://t.co/iNfEyf3G1G (@ASCO)

Congratulations @ASCO ! This is a patient-centered look at treatment of older adults with #MetBreastCancer with CDK4/6 inhibitors. #TeamScience #PatientVoice @JaniceTNBCmets @TPollastro @jrgralow @DrDawnHershman @elmayermd (@paspears88)

Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in HR-positive breast cancer, the future of ADCs in TNBC, and the importance of a shared decision-making process in breast cancer treatment. @drsarahsam @DanaFarber #bcsm #oncology https://t.co/eAR3QZt7Pa (@OncLive)

Awesome talk by Dr. @DrRanaMcKay on the future perspectives of new drugs and compounds in RCC, highlighting antibody drug conjugates, radio pharmaceutical agents, PARP inhibitors and CDK4/6 inhibitors. #KCRS23 @OncoAlert (@FabioSchutz78)

Selection and sequencing of CDK4/6 inhibitors in metastatic HR+/HER2- breast cancer hinge on the maturation of data in the first-line setting and beyond, and need to account for patient concerns and preferences. @drsarahsam @DanaFarber #bcsm #oncology https://t.co/SxrWSHh8F9 (@OncLive)

Dr McDermott discussing LOTESPARK-024 Belzutifan +/- Palbociclib in RCC hoping it’s “the next big thing coming out of ⁦@kaelin_lab⁩” #kcrs23 ⁦@kidneycan⁩ (@MosheOrnsteinMD)

Join Dr. Tolaney (@stolaney1) for a live virtual roundtable on August 8th on Implementing Guideline Recommendations for CDK 4/6 Inhibition in Early #BreastCancer. Register today and submit your questions to the panel: https://t.co/OWcM05JbP8 @Medthority https://t.co/IbSqV6MOCr (@DFCI_BreastOnc)

Listen to a discussion between the Oncology Brothers and Stephanie Graff, MD, FACP, on the role of CDK4/6 inhibition with aromatase inhibitor therapy following data from the SONIA trial in HR+ metastatic breast cancer. #bcsm | @OncBrothers @DrSGraff https://t.co/DaR4DpvQqf (@TargetedOnc)

Our novel finding on distinct mechanisms of resistance to palbociclib and abemaciclib in HR+ / HER2- MBC. Is there rationale for switching CDK4/6i after progression? @kandymarsy @KellyKhunt @MDAndersonNews @CR_AACR @HarmonyTurk https://t.co/BMmXIlJ3kt (@kandymarsy)

CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer @drsarahsam @DanaFarber @OncLiveSOSS #bcsm #oncology https://t.co/TXArfvn893 (@OncLive)

🎥@ErikaHamilton9 from @SarahCannonDocs discusses age-related results in adjuvant abemaciclib + endocrine therapy for high-risk early #BreastCancer. Patients ≥65 had similar survival, safety, and dose reduction possibilities: ➡️https://t.co/ytt8RDV8Be⬅️ #BCSM #ASCO23 @ASCO (@VJOncology)

What is the best strategy after CDK4/6 inhibitors for the treatment of HR+ breast cancer? We need high quality #RWE to address important questions that will not be answered by RCTs @DMBranco presenting the #ALINE study proposal for the @oncodistinct network @OncoAlert #bcsm (@Nader_Guilherme)

Sharing our most recent research paper on the effectiveness of palbociclib with aromatase inhibitors for advancer #breastcancer. IPOLisboa Faculdade de Farmácia da Universidade de Lisboa INFARMED, I.P. @DMBranco @ajrsferreira joint…https://t.co/C4xDFOKAi3 https://t.co/Nat0arMnK7 (@Filipa_A_C)

@stolaney1, ASCO 2023💫: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer. https://t.co/L7sdlObWex (@DFCI_BreastOnc)

3/17 #TumorBoardTuesday #BCSM @DrGattiMays @KalinskyKevin @chibaAkiko @stage4kelly @hmcarthur Keeping the 👆🏽above 👩 patient in mind. 🤔 Would you consider the continuation of CDK4/6 inhibition with a different endocrine therapy backbone? ♻️ (@IlanaSchlam)

11/17 #TumorBoardTuesday #SABCS22 ✨EMERALD✨ post hoc analysis: ❗without ESR1 mutations + PD <6mos on CDK4/6 inhibitor = elacestrant ⬆️ PFS (5.3 vs 1.9m) ❗without ESR1 mutations + PD >6mos on CDK4/6 inhibitor = elacestrant ↔️ PFS (1.9 vs 2 m) #ASCO23 #VirginiaKalkamani (@IlanaSchlam)

Gedatolisib + palbociclib & letrozole produced durable responses w/ comparable safety to that observed w/ palbociclib & letrozole alone in treatment-naïve patients withER-positive, HER2-negative advanced breast cancer @hoperugo @UCSFCancer #bcsm https://t.co/Hpc5ZFF5GJ (@OncLive)

📢Our new paper is out! Fecal microbiota composition is related to response to CDK4/6-inhibitors+ET in HR+/HER2- metastatic #breastcancer https://t.co/qSzLlKKVKC Thanks to #DanieleGenerali @curijoey @valerioiebba and all the team involved. Here the results in brief 👇🏻 (@FrancescoSche20)

Gedatolisib + palbociclib & letrozole produced durable responses w/ comparable safety to that observed w/ palbociclib & letrozole alone in treatment-naïve patients withER-positive, HER2-negative advanced breast cancer @hoperugo @UCSFCancer #bcsm https://t.co/D5Xk9qw1X0 (@OncLive)

all the metastatic hormone positive her2 negative breast cancers don’t benefit from CDK4/6 inhibitors in front line! Speaker: Barbara Pistilli #florencebreast23 @OncoAlert @acampsmalea @ChelainG @MartaPerachino @FatjonaKrajaMD @FrancicaPaola (@Dr_m_garousi)

Stay tuned ! 🙌 First session : CDK 4/6 inhibitors and RT for breast cancer with @matteolambe, Philip Poortmans, Babara Pistilli and Gustavo Nader Marta.@OncoAlert @Dr_m_garousi @MartaPerachino @FatjonaKrajaMD @ChelainG @FrancicaPaola @Icro_Meattini #FlorenceBreast23 (@acampsmalea)

Some highlights from #ASCO23 on #breastcancer studies on CDK4/6 inhibitors: results from NATALEE, monarchE, and PENELOPE-B Published by @VJOncology https://t.co/9wnOih9BJa (@ElisaAgostinett)

In this interview by @VJOncology I share a summary of the findings presented at #ASCO23 about the academic #NeoRhea trial - neoadjuvant palbociclib + ET for early ER+/HER2-neg #breastcancer https://t.co/2KtmdkZGmo (@ElisaAgostinett)

This figure shows the substantial differences in baseline risk in the 4 trials of adjuvant CDK4/6 inhibitors in ER+ breast cancer. iDFS data for the control arms (ET, only). And by design, as several trials sought to enrich for high risk tumors. Via @DrHBurstein #breastcancer (@efrenbolivar)

It’s really a shame if @AnthemBCBS is not approving ribociclib for 1st line metastatic ER+HER2- breast cancer. (@FelipeBatalini)

Waiting for similar invitation about commentary on routine use of upfront CDK 4/6 inhibitors in metastatic breast cancer (@sarojniraula)

The added cost of prolonged CDK4/6 inhibition is an issue that will continue to evolve. 'I think we need to better understand which patient population would benefit versus not.' @maryam_lustberg @YaleBreast #bcsm https://t.co/vnPXOUkbo8 @SmilowCancer @YaleMed @YNHH (@YaleCancer)

🩺 ASCO 2023 Breast Cancer 🎉 ➡️ What differences in the incidence of adverse events between younger and older patients receiving abemaciclib and endocrine therapy in the #monarchE trial? @ErikaHamilton9 @SarahCannonDocs #BreastCancer #ASCO23 🔗 https://t.co/x1gNrB6OvJ (@oncologytube)

Recently published📰: A phase I trial of #palbociclib and #bosutinib with #fulvestrant in patients with metastatic HR+ HER2- #BreastCancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor by @FilipaLynce @EDBarrowsMD @juliecollinsmd @claudine_isaacs @ppohlmann_ et al (@DFCI_BreastOnc)

Check out Dr. Nagi El Saghir @NagiSaghir @AUB_Lebanon discussing #ASCO23 Outcomes w/1st Line Ribociclib + Endocrine Tx vs. PC Combination Chemo by Age in Pre/Perimenopausal Pts w/ Aggressive HR+/HER2− Adv. BC: RIGHT Choice Trial Subgroup Analysis" #bcsm https://t.co/O7V5ZSkNlg (@Sameh_VuMedi)

🎥@PTarantinoMD of @DanaFarber highlights breast cancer updates at #ASCO23. Exciting results from NATALEE trial show ribociclib + endocrine therapy benefiting early breast cancer patients. Also discusses ADC sequencing in #BreastCancer: ➡️https://t.co/cZCZ44Kedb #ASCO23 #BCSM (@VJOncology)

Check out Dr. Michail Ignatiadis @MIgnatiadis @JulesBordet discussing #ASCO23 Primary Efficacy Analyses of NeoRHEA, #Neoadjuvant #Biomarker Research Study of Palbociclib w/Endocrine Therapy in Estrogen Receptor Positive/HER2- BC #bcsm #breastcancer @EORTC https://t.co/iwysbmWmEj (@Sameh_VuMedi)

#ASCO23 #BreastCancer #OncoAlert Take Home Message 1. NATALEE: Adjuvant Ribociclib (400mg/day) improves 3-year PFS by 3% (HR: 0.748). Need more follow-up. monarchE: Comparison of ≥65 and <65 age groups. Similar efficacy and side effects. Higher discontinuation rate in ≥65… https://t.co/LeVkLQGGNN (@teamoncology)

#ASCO23 #BreastCancer #OncoAlert Take Home Message 1. NATALEE: Adjuvant Ribociclib (400mg/day) improves 3-year PFS by 3% (HR: 0.748). Need more follow-up. monarchE: Comparison of ≥65 and <65 age groups. Similar efficacy and side effects. Higher discontinuation rate in ≥65… https://t.co/JHYMXeE0nG (@teamoncology)

#ASCO23 #BreastCancer #OncoAlert Take Home Message 1. CDK series. NATALEE: Adjuvant Ribociclib (400mg/day) improves 3-year PFS by 3% (HR: 0.748). Need more follow-up. monarchE: Comparison of ≥65 and <65 age groups. Similar efficacy and side effects. Higher discontinuation rate… https://t.co/Moi2bw2jcm (@teamoncology)

#ASCO23 #BreastCancer #OncoAlert Take Home Message 1. CDK series. NATALEE: Adjuvant Ribociclib (400mg/day) improves 3-year PFS by 3% (HR: 0.748). Need more follow-up. monarchE: Comparison of ≥65 and <65 age groups. Similar efficacy and side effects. Higher discontinuation rate… https://t.co/ZRL6nsHFOY (@teamoncology)

A clinically meaningful absolute risk reduction in iDFS & DRFS w/ abemaciclib + endocrine therapy was maintained in HR+/HER2–, high-risk early breast cancer regardless of age. @ErikaHamilton9 @SarahCannonDocs @ASCO #ASCO23 #ASCO2023 #bcsm https://t.co/8ode7rdSPz (@OncLive)

Do early stage data from #ASCO23 translate into #MBC? @DrSGraff thinks so and #OMBCL agrees. Case in point, from an oral abstract by @ErikaHamilton9, abemaciclib benefit is maintained for ALL BC patients when dose modification is utilized! #bcsm #metastaticbreastcancer (@ourmbclife)